Compass Pathways (CMPS) — Compass Pathways reported a Q2 2025 net loss of $38.4 million ($0.41 per share) and ended June with $221.9 million in cash, providing runway into 2027.
Following a positive primary-endpoint readout in its first COMP360 psilocybin Phase 3 trial in treatment-resistant depression, management said it was evaluating options for a potentially accelerated regulatory filing. The second pivotal Phase 3 trial continued enrolling, with 26-week data expected in the second half of 2026.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.